Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

NCT00770588 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

296

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Gefitinib
DRUG: Placebo

Sponsor

AstraZeneca